Quick answers
- What is Bupivacaine hydrochloride and epinephrine bitartrate used for?
- The FDA-approved label (Marcaine, Hospira, Inc., October 23, 2026) says: “MARCAINE / MARCAINE WITH EPINEPHRINE is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Bupivacaine hydrochloride and epinephrine bitartrate?
- The “Adverse Reactions” section of the FDA label (Marcaine, Hospira, Inc., October 23, 2026) begins: “The following clinically significant adverse reactions have been reported and described in the Warnings and Precautions section of the labeling: • Cardiac Arrest in Obstetrical Anesthesia [see Warnings and Precautions (5.1)] • Dose-Related Toxicity [see Warnings and Precautions (5.2)] • Methemoglobinemia [see Warnings and Precautions (5.3)] • Chondrolysis with Intra-Articular Infusion [see Warnings and Precautions (5.5)] • Severe, Persistent Hypertension, Cerebrovascular …” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the drug interactions of Bupivacaine hydrochloride and epinephrine bitartrate?
- The “Drug Interactions” section of the FDA label (Marcaine, Hospira, Inc., October 23, 2026) begins: “• Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. (7.1) • Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Bupivacaine hydrochloride and epinephrine bitartrate have a boxed warning?
- Yes. The FDA label for Marcaine has a boxed warning (“WARNING: RISK OF CARDIAC ARREST WITH USE OF MARCAINE IN OBSTETRICAL ANESTHESIA”), the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Bupivacaine hydrochloride and epinephrine bitartrate?
- The FDA drug shortage list shows “Current shortage” for a product of this medicine (updated November 9, 2026). Ask your pharmacist about alternatives.
- Has Bupivacaine hydrochloride and epinephrine bitartrate been recalled?
- FDA enforcement reports list 15 recalls of products of this medicine; the newest started November 22, 2022 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Bupivacaine hydrochloride and epinephrine bitartrate?
- 6 companies list prescription products of Bupivacaine hydrochloride and epinephrine bitartrate in the FDA NDC Directory, including Hospira, Inc., Fresenius Kabi USA, LLC and HF Acquisition Co LLC, DBA HealthFirst.
What Bupivacaine hydrochloride and epinephrine bitartrate is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
MARCAINE / MARCAINE WITH EPINEPHRINE is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. …
— FDA label: Marcaine, Hospira, Inc., effective October 23, 2026. Read the full label on DailyMed →
Label quoted: the one for the most common form (injection, solution, perineural), Marcaine, Hospira, Inc.; it covers 10 products in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
The FDA has 13 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Its heading: WARNING: RISK OF CARDIAC ARREST WITH USE OF MARCAINE IN OBSTETRICAL ANESTHESIA
. Read it on the full label →
10 of 13 FDA labels for this medicine have a boxed warning.
Bupivacaine hydrochloride and epinephrine bitartrate boxed warning: what the label says
Quoted from the boxed warning of the FDA-approved label.
WARNING: RISK OF CARDIAC ARREST WITH USE OF MARCAINE IN OBSTETRICAL ANESTHESIA There have been reports of cardiac arrest with difficult resuscitation or death during use of MARCAINE for epidural anesthesia in obstetrical patients. In most cases, this has followed use of the 0.75% (7.5 mg/mL) concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management.
Read more of this section
Cardiac arrest has occurred after convulsions resulting from systemic toxicity, presumably following unintentional intravascular injection. The 0.75% (7.5 mg/mL) concentration of MARCAINE is not recommended for obstetrical anesthesia and should be reserved for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary [see Warnings and Precautions (5.1)]. WARNING: RISK OF CARDIAC ARREST WITH USE OF MARCAINE IN OBSTETRICAL ANESTHESIA See full prescribing information for complete boxed warning. There have been reports of cardiac arrest with difficult resuscitation or death during use of MARCAINE for epidural anesthesia in obstetrical patients. In most cases, this has followed use of the 0.75% (7.5 mg/mL) concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management. Cardiac arrest has occurred after convulsions resulting from systemic toxicity, presumably following unintentional intravascular injection. The 0.75% (7.5 mg/mL) concentration of MARCAINE is not recommended for obstetrical anesthesia and should be reserved for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary (5.1).
— FDA label: Marcaine, Hospira, Inc., effective October 23, 2026. Read the full label on DailyMed →
Bupivacaine hydrochloride and epinephrine bitartrate side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The following clinically significant adverse reactions have been reported and described in the Warnings and Precautions section of the labeling:
- Cardiac Arrest in Obstetrical Anesthesia [see Warnings and Precautions (5.1)]
- Dose-Related Toxicity [see Warnings and Precautions (5.2)]
- Methemoglobinemia [see Warnings and Precautions (5.3)]
- Chondrolysis with Intra-Articular Infusion [see Warnings and Precautions (5.5)]
- Severe, Persistent Hypertension, Cerebrovascular …
— FDA label: Marcaine, Hospira, Inc., effective October 23, 2026. This is part of the section. Read the full label on DailyMed →
Bupivacaine hydrochloride and epinephrine bitartrate drug interactions
Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.
- Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. (7.1)
- Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided.
Read more of this section
(5.6, 7.2)
- Ergot-Type Oxytocic Drugs: Concurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. (5.6, 7.3)
- Nonselective Beta-Adrenergic Antagonists: Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. Concurrent use of these agents should generally be avoided. (5.6, 7.4)
- Drugs Associated with Methemoglobinemia: Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs. (7.5)
- Potent Inhalation Anesthetics: Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics. (5.13, 7.6) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with MARCAINE / MARCAINE WITH EPINEPHRINE cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1), Warnings and Precautions (5.2)]. 7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6)]. 7.3 Ergot-Type Oxytocic Drugs Concurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. Avoid use of MARCAINE WITH EPINEPHRINE concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6)]. 7.4 Nonselective Beta-Adrenergic Antagonists Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. Concurrent use of these agents should generally be avoided.
Table from the label
| Class | Examples |
|---|---|
| Nitrates/Nitrites | nitric oxide, nitroglycerin, nitroprusside, nitrous oxide |
| Local anesthetics | articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine |
| Antineoplastic agents | cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase |
| Antibiotics | dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides |
| Antimalarials | chloroquine, primaquine |
| Anticonvulsants | phenobarbital, phenytoin, sodium valproate |
| Other drugs | acetaminophen, metoclopramide, quinine, sulfasalazine |
— FDA label: Marcaine, Hospira, Inc., effective October 23, 2026. This is part of the section. Read the full label on DailyMed →
Bupivacaine hydrochloride and epinephrine bitartrate dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
- Not for intrathecal use. (2.1)
- Avoid use of solutions containing antimicrobial preservatives (i.e., multiple-dose vials) for epidural or caudal anesthesia. (2.1, 5.4)
- Three mL of MARCAINE WITH EPINEPHRINE without antimicrobial preservative (0.5% bupivacaine with 1:200,000 epinephrine) is recommended for use as a test dose prior to caudal and lumbar epidural blocks when clinical conditions permit.
Read more of this section
(2.4)
- See full prescribing information for: - Recommended concentrations and dosages of MARCAINE / MARCAINE WITH EPINEPHRINE according to type of block. (2.2) - Additional dosage and administration information pertaining to use in epidural anesthesia, test dose for caudal and lumbar epidural blocks, use in dentistry, and use in ophthalmic surgery. (2.3, 2.4, 2.5, 2.6) 2.1 Important Dosage and Administration Information
- MARCAINE / MARCAINE WITH EPINEPHRINE is not for intrathecal use.
- Avoid use of MARCAINE / MARCAINE WITH EPINEPHRINE solutions containing antimicrobial preservatives (i.e., multiple-dose vials) for epidural or caudal anesthesia [see Warnings and Precautions (5.4)].
- Discard unused portions of solution not containing preservatives, i.e., those supplied in single-dose vials, following initial use.
- Visually inspect this product for particulate matter and discoloration prior to administration whenever solution and container permit. MARCAINE / MARCAINE WITH EPINEPHRINE are clear, colorless solutions. Do not administer solutions which are discolored or contain particulate matter.
- Mixing or the prior or intercurrent use of any other local anesthetic with MARCAINE / MARCAINE WITH EPINEPHRINE is not recommended because of insufficient data on the clinical use of such mixtures. Administration Precautions
- MARCAINE / MARCAINE WITH EPINEPHRINE are to be administered in carefully adjusted dosages by or under the supervision of experienced clinicians who are well versed in the diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed.
- Use MARCAINE / MARCAINE WITH EPINEPHRINE only if the following are immediately available: oxygen, cardiopulmonary resuscitative equipment and drugs, and the personnel resources needed for proper management of toxic reactions and related emergencies [see Warnings and Precautions (5.2), Adverse Reactions (6), Overdosage (10)].
- The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects related to local anesthetic systemic toxicity when additional local anesthetics are administered with MARCAINE / MARCAINE WITH EPINEPHRINE [see Warnings and Precautions (5.2), Drug Interactions (7.1), Overdosage (10)].
- Aspirate for blood or cerebrospinal fluid (where applicable) prior to injecting MARCAINE / MARCAINE WITH EPINEPHRINE, both the initial dose and all subsequent doses, to avoid intravascular or intrathecal injection. However, a negative aspiration for blood or cerebrospinal fluid does not ensure against an intravascular or intrathecal injection [see Warnings and Precautions (5.9)].
Table from the label
| MARCAINE Concentration | Motor Function |
|---|---|
| 0.25% (2.5 mg/mL)These products include MARCAINE and MARCAINE WITH EPINEPHRINE [the epinephrine concentration (1:200,000) is not included in the table]. | When used for caudal, epidural, or peripheral nerve block, produces incomplete motor block. Should be used for operations in which muscle relaxation is not important, or when another means of providing muscle relaxation is used concurrently. Onset of action may be slower than with the 0.5% (5 mg/mL) or 0.75% (7.5 mg/mL) solutions. |
| 0.5% (5 mg/mL) | Provides motor blockade for caudal, epidural, or nerve block, but muscle relaxation may be inadequate for operations in which complete muscle relaxation is essential. |
| 0.75% (7.5 mg/mL)These are only MARCAINE products [there is no 0.75% (7.5 mg/mL) concentration for MARCAINE WITH EPINEPHRINE]. | Produces complete motor block. Most useful for epidural block in abdominal operations requiring complete muscle relaxation, and for retrobulbar anesthesia. Not for obstetrical anesthesia. |
— FDA label: Marcaine, Hospira, Inc., effective October 23, 2026. This is part of the section. Read the full label on DailyMed →
Bupivacaine hydrochloride and epinephrine bitartrate in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Risk Summary MARCAINE / MARCAINE WITH EPINEPHRINE is contraindicated for obstetrical paracervical block anesthesia. Its use in this technique has resulted in fetal bradycardia and death [see Contraindications (4), Warnings and Precautions (5.1)]. There are no available data on use of MARCAINE / MARCAINE WITH EPINEPHRINE in pregnant women to inform a drug-associated risk of adverse developmental outcomes.
Read more of this section
In animal studies, embryo-fetal lethality was noted when bupivacaine was administered subcutaneously to pregnant rabbits during organogenesis at clinically relevant doses. Decreased pup survival was observed in a rat pre- and post-natal developmental study (dosing from implantation through weaning) at a dose level comparable to the daily maximum recommended human dose (MRHD) on a body surface area (BSA) basis. Based on animal data, advise pregnant women of the potential risks to a fetus (see Data). Local anesthetics rapidly cross the placenta, and when used for epidural, caudal, or pudendal block anesthesia, can cause varying degrees of maternal, fetal, and neonatal toxicity [see Clinical Pharmacology (12.3)]. The incidence and degree of toxicity depend upon the procedure performed, the type, and amount of drug used, and the technique of drug administration. Adverse reactions in the parturient, fetus, and neonate involve alterations of the CNS, peripheral vascular tone, and cardiac function. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, inform the patient of the potential hazard to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively. Clinical Considerations Maternal Adverse Reactions Maternal hypotension has resulted from regional anesthesia. Local anesthetics produce vasodilation by blocking sympathetic nerves. The supine position is dangerous in pregnant women at term because of aortocaval compression by the gravid uterus. Therefore, during treatment of systemic toxicity, maternal hypotension or fetal bradycardia following regional block, the parturient should be maintained in the left lateral decubitus position if possible, or manual displacement of the uterus off the great vessels be accomplished. Elevating the patient's legs will also help prevent decreases in blood pressure. The fetal heart rate also should be monitored continuously and electronic fetal monitoring is highly advisable. Labor or Delivery Epidural, caudal, or pudendal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts. Epidural anesthesia has been reported to prolong the second stage of labor by removing the parturient's reflex urge to bear down or by interfering with motor function. The use of obstetrical anesthesia may increase the need for forceps assistance. The use of some local anesthetic drug products during labor and delivery may be followed by diminished muscle strength and tone for the first day or two of life.
— FDA label: Marcaine, Hospira, Inc., effective October 23, 2026. This is part of the section. Read the full label on DailyMed →
When Bupivacaine hydrochloride and epinephrine bitartrate should not be used
Quoted from the “Contraindications” section of the FDA-approved label.
MARCAINE / MARCAINE WITH EPINEPHRINE is contraindicated in:
- obstetrical paracervical block anesthesia. Its use in this technique has resulted in fetal bradycardia and death.
- intravenous regional anesthesia (Bier Block) [see Warnings and Precautions (5.7)].
- patients with a known hypersensitivity to bupivacaine or to any local anesthetic agent of the amide-type or to other components of MARCAINE / MARCAINE WITH EPINEPHRINE.
- Obstetrical paracervical block anesthesia.
Read more of this section
Its use in this technique has resulted in fetal bradycardia and death. (4)
- Intravenous regional anesthesia (Bier Block). (4)
- Known hypersensitivity to bupivacaine or to any local anesthetic agent of the amide-type or to other components of MARCAINE / MARCAINE WITH EPINEPHRINE. (4)
— FDA label: Marcaine, Hospira, Inc., effective October 23, 2026. Read the full label on DailyMed →
Bupivacaine hydrochloride and epinephrine bitartrate overdose
Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).
Clinical Presentation Acute emergencies from use of MARCAINE / MARCAINE WITH EPINEPHRINE are generally related to high plasma levels encountered during therapeutic use or to unintended intrathecal injection [see Warnings and Precautions (5.2, 5.9), Adverse Reactions (6)].
Read more of this section
If not treated immediately, convulsions with simultaneous hypoxia, hypercarbia, and acidosis plus myocardial depression from the direct effects of bupivacaine may result in cardiac arrhythmias, bradycardia, asystole, ventricular fibrillation, or cardiac arrest. Respiratory abnormalities, including apnea, may occur. Hypoventilation or apnea due to unintentional intrathecal injection of MARCAINE / MARCAINE WITH EPINEPHRINE may produce these same signs and also lead to cardiac arrest if ventilatory support is not instituted. If cardiac arrest should occur, successful outcome may require prolonged resuscitative efforts. Management The first step in the management of systemic toxic reactions, as well as hypoventilation or apnea due to unintentional intrathecal injection of MARCAINE / MARCAINE WITH EPINEPHRINE, consists of immediate attention to the establishment and maintenance of a patent airway and effective assisted or controlled ventilation with 100% oxygen with a delivery system capable of permitting immediate positive airway pressure by mask. Endotracheal intubation, using drugs and techniques familiar to the clinician, may be indicated after initial administration of oxygen by mask if difficulty is encountered in the maintenance of a patent airway, or if prolonged ventilatory support (assisted or controlled) is indicated. If necessary, use drugs to manage the convulsions. A bolus intravenous dose of a benzodiazepine will counteract CNS stimulation related to MARCAINE. Immediately after the institution of ventilatory measures, evaluate the adequacy of the circulation. Supportive treatment of circulatory depression may require Advanced Cardiac Life Support measures.
— FDA label: Marcaine, Hospira, Inc., effective October 23, 2026. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Injection, solution |
|---|---|
| Route | Perineural · Epidural · Infiltration · Intracaudal · Submucosal · Retrobulbar |
| Prescription products | 25 in the FDA NDC Directory |
| Brand names | Marcaine with Epinephrine, Sensorcaine Mpf, Sensorcaine, Vivacaine, Marcaine |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Hospira, Inc.14 products
- Fresenius Kabi USA, LLC7 products
- HF Acquisition Co LLC, DBA HealthFirst2 products
- Septodont, Inc.2 products
- Henry Schein, Inc.1 product
- Sportpharm LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA016964 MARCAINE HYDROCHLORIDE, MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE | Hospira | October 3, 1972 | 52, latest August 21, 2020 2020: Labeling · 2018: Labeling · 2014: Manufacturing (CMC) |
| NDA018304 SENSORCAINE | Fresenius Kabi USA | December 30, 1981 | 26, latest July 19, 2022 2022: Labeling · 2018: Labeling · 2016: Manufacturing (CMC) |
Generic approvals (8)
- ANDA070966Fresenius Kabi USA · October 13, 1987
- ANDA070967Fresenius Kabi USA · October 13, 1987
- ANDA070968Fresenius Kabi USA · October 13, 1987
- ANDA071165Hospira · June 16, 1988
- ANDA071167Hospira · June 16, 1988
- ANDA071168Hospira · June 16, 1988
- ANDA071170Hospira · June 16, 1988
- ANDA077250Septodont · September 27, 2006
Shortage status
Current shortage · updated November 9, 2026 · first posted February 20, 2018
| Product | Marcaine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-5010-01) |
|---|---|
| Availability | Available |
| Company | Hospira, Inc., a Pfizer Company |
Ask your pharmacist whether your product is affected and what the options are.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
November 22, 2022 · Class II · Terminated · D-0127-2023
Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.
Sensorcaine (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.25%, 125 mg per 50 mL (2.5 mg per mL), 50 mL Multiple Dose Vial (NDC 63323-461-01), packaged in 25 Multiple Dose — Fresenius Kabi USA, LLC
-
November 22, 2022 · Class II · Terminated · D-0129-2023
Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.
Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.25%, 25 mg per 10 mL (2.5 mg per mL), 10 mL Single Dose Vial (NDC 63323-468-01), packaged in 25 Single Dose V — Fresenius Kabi USA, LLC
-
November 22, 2022 · Class II · Terminated · D-0128-2023
Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.
Sensorcaine (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.5%, 250 mg per 50 mL (5 mg per mL), 50 mL Multiple Dose Vial (NDC 63323-463-01), packaged in 25 Multiple Dose Via — Fresenius Kabi USA, LLC
-
April 13, 2022 · Class II · Terminated · D-1095-2022
cGMP deviations: Temperature abuse
Bupivacaine Hydrochloride, USP 0.5% (5mg/mL), 25 vials x 50 mL per box, Rx only, MFG: Pfizer, NDC 0409-1163-01 — Mckesson Medical-Surgical Inc. Corporate Office
-
May 3, 2021 · Class I · Terminated · D-0626-2021
Labeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USP
0.5% Bupivacaine Hydrochloride Injection, USP, 150 mg/30 mL (5 mg/mL), 30 mL Single-dose Teartop Vials (NDC 0409-1162-19), packaged in 25 vials per tray (NDC 0409-1162-02), Rx only, Distributed by Hospira, Inc., Lake For — PFIZER, INC
-
December 10, 2020 · Class II · Terminated · D-0172-2021
Subpotent Drug: Low out-of-specification assay results for the epinephrine component.
Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP), 0.5%, 150 mg per 30 mL (5 mg per mL), 30 mL Single Dose Vial (NDC 63323-462-01), packaged as 25 Single Dose Vials per tray (NDC 63323-462-37), Rx only, Fr — Fresenius Kabi USA, LLC
-
August 4, 2016 · Class I · Ongoing · D-0218-2017
Presence of particulate matter: Confirmed customer report for the presence of particulate matter within a single vial.
Bupivacaine Hydrochloride Inj., USP (2.5 mg/mL) 0.25%, packaged in 30 mL Single-dose Preservative-Free vials, Rx Only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-1159-02 — Hospira Inc., A Pfizer Company
-
April 25, 2016 · Class II · Terminated · D-1037-2016
Presence of Particulate Matter: Glass particulate found in sterile injectable product
Sensorcaine- MPF (Bupivacaine HCI Injection, USP), 0.75% in a 30 mL Single Dose Vial, Rx only, Fresenius Kabi USA LLC, Lake Zurich, IL 60047, NDC 63323-472-37 — Fresenius Kabi USA, LLC
-
April 23, 2015 · Class I · Terminated · D-1216-2015
Presence of Particulate Matter: Presence of free-floating and embedded iron oxide particles.
Bupivacaine Hydrochloride Inj., USP, 0.5% (5 mg/mL), Preservative-Free, 30 mL Single Use Vials, Rx only. HOSPIRA, INC., LAKE FOREST, IL 60045 USA. NDC: 0409-1162-02. — Hospira Inc.
-
September 4, 2014 · Class II · Terminated · D-1588-2014
Presence of Particulate Matter: A confirmed customer complaint reported the presence of a brown, rust-colored particle embedded at the bottom of the glass vial.
Bupivacaine HCl Inj., USP, 0.5% (5 mg/mL), 30 mL Single-dose Preservative-Free, For Nerve Block, Caudal, and Epidural Anesthesia, Not for Spinal Anesthesia, Rx Only, Hospira, Inc., Lake Forest, IL 60045 USA, NDC 0409-116 — Hospira Inc.
-
February 10, 2014 · Class II · Terminated · D-1147-2014
Presence of Particulate Matter: Confirmed customer report of visible particulate embedded in the glass vial.
Bupivacaine HCl Inj. USP, 0.5% (5 mg/mL), 30 mL Single-dose Preservative Free Vial, Rx Only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-1162-02 — Hospira Inc.
-
October 11, 2013 · Class II · Terminated · D-395-2014
Lack of assurance of sterility; equipment failure led to potential breach in asceptic process.
0.5% Bupivacaine HCl and Epinephrine 1:200,000 Inj., 50 mL, Multiple-dose Fliptop Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045. NDC #0409-9046-01. — Hospira Inc.
-
September 5, 2013 · Class II · Terminated · D-66295-001
Lack of Assurance of Sterility; potential for vial breakage
0.5% Bupivacaine HCl and Epinephrine 1:200,000 Inj., 10 mL, Single-Dose Vial, NDC 0409-9045-01, Hospira, Inc., Lake Forest, IL 60045 — Hospira Inc.
-
July 12, 2013 · Class I · Terminated · D-381-2014
Presence of particulate matter: visible free floating and partially embedded particulate matter in the glass vials.
0.75% Bupivacaine HCl Injection, USP, 7.5 mg/mL, 30 mL, Single-dose, Hospira Inc., Lake Forest, IL 60045, NDC 0409-1165-02 — Hospira Inc.
-
July 12, 2013 · Class I · Terminated · D-380-2014
Presence of particulate matter: visible free floating and partially embedded particulate matter in the glass vials.
0.25% Bupivacaine HCl Injection, USP, 2.5 mg/mL, 30 mL, Single-dose, Hospira Inc., Lake Forest, IL 60045, NDC 0409-1159-02 — Hospira Inc.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- Marcaine with EpinephrineBrand page: products, maker and price
- SensorcaineBrand page: products, maker and price
- Sensorcaine MpfBrand page: products, maker and price
- Bupivacaine Hci and EpinephrineBrand page: products, maker and price
- Hospira, Inc.Maker or distributor
- Fresenius Kabi USA, LLCMaker or distributor
- HF Acquisition Co LLC, DBA HealthFirstMaker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Marcaine, Hospira, Inc., effective October 23, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →